Cantor Fitzgerald Lowers Earnings Estimates for Codexis

Codexis, Inc. (NASDAQ:CDXS - Free Report) - Research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for shares of Codexis in a report released on Thursday, May 15th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biotechnology company will post earnings per share of ($0.62) for the year, down from their prior estimate of ($0.60). The consensus estimate for Codexis' current full-year earnings is ($0.77) per share.

Separately, StockNews.com upgraded Codexis to a "sell" rating in a research note on Friday.

Codexis Trading Down 1.6%

Shares of NASDAQ:CDXS opened at $2.47 on Monday. The company has a quick ratio of 3.15, a current ratio of 3.21 and a debt-to-equity ratio of 0.39. Codexis has a 52-week low of $1.90 and a 52-week high of $6.08. The stock has a market cap of $204.63 million, a price-to-earnings ratio of -2.84 and a beta of 2.56. The business has a 50-day moving average price of $2.44 and a 200-day moving average price of $3.74.

Codexis (NASDAQ:CDXS - Get Free Report) last announced its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.05). The business had revenue of $7.54 million for the quarter, compared to analysts' expectations of $10.38 million. Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%.

Institutional Investors Weigh In On Codexis

Several hedge funds and other institutional investors have recently bought and sold shares of CDXS. Summit Investment Advisors Inc. lifted its stake in shares of Codexis by 81.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,428 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 3,783 shares during the last quarter. US Bancorp DE lifted its position in Codexis by 11,125.0% in the first quarter. US Bancorp DE now owns 17,960 shares of the biotechnology company's stock valued at $48,000 after buying an additional 17,800 shares during the last quarter. Wolverine Trading LLC purchased a new position in Codexis during the fourth quarter worth about $56,000. Fiduciary Trust Co acquired a new stake in shares of Codexis during the fourth quarter valued at about $65,000. Finally, Group One Trading LLC purchased a new stake in shares of Codexis in the 4th quarter valued at approximately $73,000. 78.54% of the stock is currently owned by institutional investors and hedge funds.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.